ArticleAmerican journal of translational research2026
MUS81 inhibits cell proliferation and migration in breast cancer by promoting the expression of CDKN2A(p16
Article in American journal of translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
MUS81 has been recognized as a significant tumor suppressor - essential for DNA damage repair and maintaining chromosomal stability. However, its biological function and expression profile in breast cancer (BC) remain unclear. In this investigation, we examined the relationship between MUS81 expression and the proliferative and migratory capacities of BC cells. MUS81 mRNA and protein levels were markedly lower in breast cancer tissues and cell lines than in adjacent normal tissues and non-tumorigenic MCF-10A cells. Functional assays revealed that MUS81 overexpression suppressed, while MUS81 silencing enhanced, BC cell proliferation and motility, as demonstrated by CCK-8, colony formation, wound-healing, and Transwell experiments. In vivo, MUS81 overexpression markedly reduced Ki-67 expression in xenograft tumors. Although MUS81 did not alter CDKN2A mRNA expression, immunohistochemistry and Western blot analyses showed that p16
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.